Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PLIMATH
A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma
- NCT03331731 ↗
- Completed
- Peter MacCallum Cancer Centre, Australia
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on PLIMATH (pembrolizumab in Hodgkin lymphoma unsuitable for ABVD) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PLIMATH so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Multi-centre Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma Considered Unsuitable for ABVD
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Hodgkin Lymphoma
- Interventions
- pembrolizumab
- Arms
- Single arm · Experimental
- Enrollment
- 27
- Primary outcomes
- Response using Lugano Criteria
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Start
- Nov 29, 2018
- Primary completion
- Feb 16, 2023
- Results posted
- No
- Registry record
- NCT03331731 · updated Nov 2, 2026